Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

Table 4 Comparison of factors between patients with and without sustained virological response

Factors	SVR, n = 258	Non-SVR, n = 7	P value
Age in yr, n (range)	68 (17-86)	74 (39-79)	0.682
Sex as male/female	146/112	4/3	1.000
Height in cm	160.1 (134.0-182.0)	161.5 (155.0-177.0)	0.350
Body weight in kg	58.0 (32.3-99.3)	63.2 (54.0-66.2)	0.267
BMI in kg/m2	22.6 (15.5-38.0)	22.6 (20.2-25.9)	0.778
Cirrhosis	87	4	0.237
CKD	51	2	0.630
History of HCC treatment	30	3	0.044
History of IFN-based therapy	61	2	0.672
HCV-RNA as logIU/mL	6.1 (2.7-7.6)	6.3 (3.3-7.0)	0.713
White blood cells as /mm3	5005 (1810-13260)	4100 (2260-8700)	0.581
Hemoglobin in g/dL	13.6 (10.2-20.1)	12.5 (11.6-14.7)	0.793
Platelets as × 104/mm3	16.2 (4.6-38.9)	14.9 (9.9-30.3)	0.930
AST in IU/L	42 (12-252)	37 (19-90)	0.789
ALT in IU/L	39 (6-394)	57 (19-79)	0.843
γ-GTP in IU/L	32 (5-888)	36 (13-461)	0.942
AFP in ng/mL	5.2 (1.0-445.0)	10.6 (1.3-29.7)	0.521
eGFR in mL/min/1.73 m2	73.1 (30-240.2)	72.2 (50.5-105.8)	0.166
Ribavirin adherence in %	100 (28-100)	100 (100-100)	0.323

Values are expressed as median (range) or number of patients. γ-GTP: γ-glutamyl transferase; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CKD: Chronic renal disease; eGFR: Estimated glomerular filtration rate; HCC: hepatocellular carcinoma; HCV: Hepatitis C virus; HCV-RNA: Hepatitis C virus-ribonucleic acid; IFN: Interferon; SVR: Sustained virological response.